Add-on lacosamide: A retrospective study on the relationship between serum concentration, dosage, and adverse events

Epilepsy and Behavior

Volumn 22, Issue 3, 2011, Pages 548-551

  Hillenbrand, Barbara ^a   Wisniewski, Ilona ^a   Jürges, Uta ^a   Steinhoff, Bernhard J ^a  

^a Epilepsy Centre Kork   (Germany)

Author keywords

Lacosamide; Serum concentration; Sodium channel blockers; Therapeutic range; Weight related dosage

Indexed keywords

CARBAMAZEPINE; CLOBAZAM; ESLICARBAZEPINE ACETATE; ETIRACETAM; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PREGABALIN; RUFINAMIDE; SODIUM CHANNEL BLOCKING AGENT; SULTIAME; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CONTROLLED STUDY; COORDINATION DISORDER; DIPLOPIA; DIZZINESS; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG SAFETY; EPILEPSY; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TREMOR; VISUAL DISORDER; VOMITING;

ACETAMIDES; ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EPILEPSY; FEMALE; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 80055014227     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2011.08.032     Document Type: Article

References (19)

1. Ben-Menachem E., Biton V., Jatuzis D., Abou-Khalil B., Doty P., Rudd G.D. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007, 48:1308-1317.
2. Chung S., Sperling M.R., Biton V., et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010, 51:958-967.
3. Halász P., Kälviäinen R., Mazurkiewicz-Bedzinska M., et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009, 50:443-453.
4. Curia G., Biagini G., Perucca E., Avoli M. Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs 2009, 23:555-568.
5. Jürges U., Steinhoff B.J. Therapeutic drug monitoring of antiepileptic drugs. Z Epileptol 2011, 24:26-33.
6. Steinhoff B.J., Fröscher W. Importance of therapeutic drug monitoring of anticonvulsants: an overview. Z Epileptol 2011, 24:6-11.
7. Patsalos P.N., Berry D.J., Bourgeois B.F., et al. Antiepileptic drugs: best practice guidelines for therapeutic drug monitoring-a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008, 49:1239-1276.
8. Sabers A. Pharmacokinetic interactions between contraceptives and antiepileptic drugs. Seizure 2008, 17:141-144.
9. Sabers A., Ohman I., Christensen J., Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003, 26:570-571.
10. Tran T.A., Leppik I.E., Blesi K., Sathanandan S.T., Remmel R. Lamotrigine clearance during pregnancy. Neurology 2002, 59:251-255.
11. Fröscher W., Schier K.R., Hoffmann M., et al. Topiramate: a prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy. Epileptic Disord 2005, 7:237-248.
12. Sake J.-K., Hebert D., Isojärvi J., et al. A pooled analysis of lacosamide clinical trial data grouped by mechanisms of action of concomitant antiepileptic drugs. CNS Drugs 2010, 24:1055-1068.
13. Novy J., Patsalos P.N., Sander J.W., Sisodiya S.M. Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction?. Epilepsy Behav 2011, 20:20-23.
14. Steinhoff B.J. Oxcarbazepine extended-release formulation in epilepsy. Expert Rev Clin Pharmacol 2009, 2:155-162.
15. Almeida L., Soares-da-Silva P. Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics 2007, 4:88-96.
16. Beyreuther B.K., Freitag J., Heers C., Krebsfänger N., Scharfenecker U., Stöhr T. Lacosamide: a review of preclinical properties. CNS Drug Rev 2007, 13:21-42.
17. Errington A.C., Stöhr T., Heers C., Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008, 73:157-169.
18. Stefan H., Kerling F., Steinhoff B.J. First clinical experiences with lacosamide treatment. Z Epileptol 2010, 23:98-103.
19. Steinhoff B.J. How to replace lamotrigine with valproate. Epilepsia 2006, 47:1943-1944.